Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Axsome Therapeutics, Inc. - Common Stock (NQ:AXSM)

128.57 +1.51 (+1.19%)
Streaming Delayed Price Updated: 2:01 PM EDT, Oct 24, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axsome Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Demystifying Axsome Therapeutics: Insights From 11 Analyst Reviews
 
Via Benzinga
Axsome Stock Slips Pre-Market After FDA Issues Refusal-To-File Letter: Retail’s Skeptical On Likelihood Of Year-End Profitability
The regulator said that upon preliminary review, it found that the new drug application for AXS-14 was not sufficiently complete to permit a substantive review. 
Via Stocktwits
Topics Stocks
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia
From Axsome Therapeutics, Inc.
Via GlobeNewswire
2 Soaring Stocks Wth More Upside Potential
Via The Motley Fool
Earnings Scheduled For May 5, 2025
 
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics Presents Data from Three of Its Innovative Neuroscience Programs at the American Society of Clinical Psychopharmacology (ASCP) 2025 Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Why Is Teva Stock Trading Higher On Tuesday?
Teva starts IND-enabling studies for BD9, a dual-target therapy for asthma and atopic dermatitis, under license from Biolojic Design. 
Via Benzinga
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.
From Axsome Therapeutics, Inc.
Via GlobeNewswire
3 High-Flying Stocks That Could Soar Even More
Via The Motley Fool
Expert Outlook: Axsome Therapeutics Through The Eyes Of 16 Analysts
 
Via Benzinga
Is Axsome Therapeutics Stock Worth the Risk? A Comprehensive Analysis
Via The Motley Fool
Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Prediction: These 2 Stocks Will Outperform the Market in the Next Five Years
Via The Motley Fool
3 Monster Stocks in the Making
Via The Motley Fool
Axsome Therapeutics Clocks Around 60% Topline Growth In Q1
Axsome beat Q1 expectations with $121.5 million in revenue and strong Auvelity sales as it prepares Symbravo's U.S. launch and advances key drug programs. 
Via Benzinga
Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Deep Dive Into Axsome Therapeutics Stock: Analyst Perspectives (28 Ratings)
 
Via Benzinga
Axsome Therapeutics to Participate in Upcoming Investor Conferences
From Axsome Therapeutics, Inc.
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS HAVE SURVIVED MOTIONS TO DISMISS: Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); and Virtu Financial Inc. (NASDAQ: VIRT)
From Grabar Law Office
Via GlobeNewswire
Attention Long-Term Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); Driven Bands Holdings, Inc. (NASDAQ: DRVN); Integra Lifesciences Holdings Corporation (NASDAQ: IART); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates
From Grabar Law Office
Via GlobeNewswire
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5
From Axsome Therapeutics, Inc.
Via GlobeNewswire
This Reddit Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions
From Grabar Law Office
Via GlobeNewswire
SECURITIES FRAUD CLASS ACTIONS SURVIVE MOTIONS TO DISMISS: Grabar Law Office Investigates Claims on Behalf of Shareholders of Arqit Quantum Inc. (NASDAQ: ARQQ); Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); and Maison Solutions
From Grabar Law Office
Via GlobeNewswire
Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting
From Axsome Therapeutics, Inc.
Via GlobeNewswire
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Why Shares of Axsome Therapeutics Slumped Today
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.